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Letters to the Editors or Brief Communication
A Validated Tool for Psychiatric Comorbidity 
in the Patients With Functional Dyspepsia
TO THE EDITOR: We read the article by Tse et al.
1 with in-
terest, which showed the usefulness of 12-item General Health 
Questionnaire (GHQ-12) as a reliable screening tool for psychi-
atric disorders in the patients with functional dyspepsia. 
Interesting studies were recently published showed anxiety to be 
linked to functional dyspepsia and especially postprandial distress 
syndrome, but not epigastric pain syndrome.
2,3 Also the system-
atic review about the efficacy of antianxiety or antidepressive 
agents on functional dyspepsia showed significant treatment bene-
fit (pooled relative risk for sustained symptoms, 0.55; 95% con-
fidence interval, 0.36-0.85), although funnel plots were 
asymmetric.
4 Whether psychological factors are causally linked to 
functional dyspepsia is controversial. In a prospective cohort 
study, there was no difference in mental distress or fear of serious 
illness in functional versus organic gastointestinal diseases, and 
gastrointestinal symptom reduction related to alleviation of men-
tal distress only reached statistical significance in patients with or-
ganic disease.
5 Psychologic comorbidity might be related to un-
derlying pathophysiology and influence the disease course, treat-
ment modality and the health care utilization. Therefore, the eval-
uation of psychiatric comorbidity in patients with functional dys-
pepsia is important. The sensitivity and specificity of GHQ-12 
were 63.0% and 92.9%, respectively when the cut-off of 
GHQ-12 was at ≥ 3 in this study. It suggests GHQ-12 as an 
acceptable screening tool to detect psychiatric disorders in the pa-
tients with functional dyspepsia. In many previous studies, the 
Symptom Checklist-90-Revised (SCL-90-R) has been selected 
for assessment of psychological status in the patients with func-
tional dyspepsia.
6,7 The SCL-90-R is another self-report ques-
tionnaire, a clinical symptom rating scale consisting of 90 
questions. GHQ-12 is a simpler screening tool for general practi-
tioner to define the psychological comorbidity in dyspepsia than 
the SCL-90-R. The proportion of the patients with previously di-
agnosed psychiatric disorders is slightly high (49.1%, 27 sub-
jects) in this study. It would be related with measurement bias, 
such as recall bias, and exposure suspicion bias.
In conclusion, the testing of psychiatric comorbidity in func-
tional dyspepsia might be worthy and GHQ-12 is a simple 
screening tool for evaluating the psychiatric profile in functional 
dyspepsia. 
Jong Chan Lee, MD
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Comments on Tegaserod Trial on Irritable 
Bowel Syndrome
TO THE EDITOR:  Irritable bowel syndrome (IBS) remains 
to be a challenge for the gastroenterologist, due to its high preva-
lence and impacts on poor quality of life (QOL) with unsat-
isfactory pharmacological treatments. Most of the current treat-
ment modalities for IBS have been directed at symptom relief 
rather than pathophysiology of the condition, which is hetero-
genous and poorly understood.
1 I read the recent articles by Kim 
et al.
2 about the tegaserod effects on IBS with great interest. The 
efficacy and safety of tegaserod have been demonstrated by sev-
eral large randomized controlled trials.
3,4 However, tegaserod 
was taken off the market by a high chance of having a myocardial 
infarction, stroke or angina.
5 
Kim et al.
2 showed the efficacy of 5-hydroxytryptamine 4 
(5-HT4) agonist in Korean women with IBS with constipation. 
In this study, tegaserod showed the relief of overall IBS symp-
toms such as abdominal pain/discomfort, number of bowel move-
ments and stool consistency. They used the composite score of 
symptom frequency and severity as an endpoint in treatment of 
IBS. The previously published pharmaceutical trial for IBS have 
used “adequate relief of abdominal pain and discomfort” or 
“satisfactory relief of IBS symptoms” as their primary outcome 
measure which led to approvals for alosetron and tegaserod by the 
Food and Drug Administration (FDA).
6 An alternative method 
for defining a responder in an IBS treatment trial is to ask pa-
tients to report the frequency and severity of all IBS symptoms. 
Kim et al.
2 showed the adequate symptom relief and good correla-
tion between symptom composite score and IBS-QOL, which 
might show the usefulness of Korean IBS-QOL in IBS ther-
apeutic trial. However, it is not clear whether reduction of 
sum-score of 22.5/96 (23.5%) was enough to define a responder. 
They conducted this trial as open arm without placebo control. 
The FDA have recommended investigators to provide rules, a 
priori, which allow classification of each participant as a res-
ponder or non-responder for the primary outcome.
7 The secon-
dary outcome is used to strengthen the results by showing con-
cordance between individual symptoms and the primary outcome 
measure, addressing the mechanism of the intervention, and as-
sessing the safety.
6 Kim et al.
2 also proposed QOL to be included 
as a therapeutic outcome. 
Recently, there are many pharmaceutical trials including the 
next generation 5-HT agonists, such as Prucalopride, TD-5108, 
and ATI-7505 in IBS.
8 I am hoping for the present study to 
strengthen the pharmaceutical research in IBS. The primary out-
come variables provide the basis for judging the success or failure 
of an intervention, therefore, further studies on the outcome 
measurements in IBS drug trials, which can properly quantify 
drug responses, are warranted. 
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Reply.  We appreciate the comments from Dr. Hye-Kyung 
Jung. There have been several issues in clinical trials on irritable 
bowel syndrome (IBS) such as duration of trial, study design, on 
demand or repeated cycles of treatment, and optimal efficacy 
endpoint.
1,2 Among these, optimal endpoint issue is one of the 
most important factors to prove efficacy of therapeutic agent in a 
clinical trial,
3 however, widely accepted and validated outcome Letters to the Editors or Brief Communication
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measures is unavailable at present. Contrary to other gastro-
intestinal diseases such as gastroesophageal reflux disease or in-
flammatory bowel disease which are diagnosed and assessed by 
endoscopy, laboratory, and radiologic evaluation, successful 
treatment of IBS in outpatient office or assessment of  effect in 
IBS clinical trial could be measured only by symptom 
improvement.
4 
Binary endpoints, such as adequate relief and satisfactory re-
lief, have been used most commonly as primary endpoint in most 
IBS clinical trials. However there is a question whether it is 
enough as primary endpoint
5,6 therefore it should be reinforced 
by secondary (supportive) efficacy endpoints in the clinical 
research. Although IBS symptom and quality of Life (QOL) 
score could be used as secondary endpoint, the utility of QOL 
score in IBS clinical trial has not been explored as satisfactory
7 
and some authors suggest that QOL score should be considered 
as a tertiary endpoint.
4 
One of the important purposes of our study was to validate 
the usefulness of QOL as an endpoint and we found that QOL 
score was comparable to symptom score in IBS clinical trial. 
QOL provides important information to clinicians about the as-
pects of health care that “actually get to the patient”
8 and The 
European Agency for the Evaluation of Medicinal Product and 
Rome III committee emphasized QOL assessments as important 
secondary outcomes.
2,9 
The problem is that there has been no consensus about the 
definition of responder in the  outcomes by symptoms or QOL 
scoring system. We were also troubled with the definition of 
“clinically meaningful change” in scoring system when we de-
signed our study protocol. The magnitude of score changes 
which means clinically important improvement in individual 
symptom or QOL has not been defined in IBS trials.
2 Some 
studies considered as little as 10% reduction in visual analog scale 
rating of symptom severity
10 or 1 step on 7-step ordinal scale
9 as 
clinically meaningful, whereas other studies used 50% reduction 
in an aggregate symptom severity index
11 or questionnaire.
5 A 
statistically significant p-value also does not imply whether a par-
ticular finding is “clinically meaningful change.” 
Therefore we recommend clinical researchers to use QOL as 
an endpoint in IBS clinical trials and hope that further studies 
will be carried out to figure out what is the magnitude of 
“clinically meaningful change” in symptoms and QOL scoring 
system. 
Yong Sung Kim, MD
Suck Chei Choi, MD
  Department of Internal Medicine
Wonkwang Digestive Disease Research Institute
Wonkwang University School of Medicine
Iksan, Jeollabuk-do, Korea
1. Corazziari E, Bytzer P, Delvaux M, et al. Clinical trial guidelines for 
pharmacological treatment of irritable bowel syndrome. Aliment 
Pharmacol Ther 2003;18:569-580.
2. Design of Treatment Trials Committee, Irvine EJ, Whitehead WE, 
et al. Design of treatment trials for functional gastrointestinal 
disorders. Gastroenterology 2006;130:1538-1551.
3. Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, 
Talley NJ. Primary endpoints for irritable bowel syndrome trials: a 
review of performance of endpoints. Clin Gastroenterol Hepatol 
2007;5:534-540.  
4. Schoenfeld P, Talley NJ. Measuring successful treatment of irritable 
bowel syndrome: is “satisfactory relief” enough? Am J Gastroenterol 
2006;101:1066-1068.
5. Whitehead WE, Palsson OS, Levy RL, Feld AD, VonKorff M, 
Turner M. Reports of “satisfactory relief” by IBS patients receiving 
usual medical care are confounded by baseline symptom severity and 
do not accurately reflect symptom improvement. Am J Gastroenterol 
2006;101:1057-1065. 
6. Passos MC, Lembo AJ, Conboy LA, et al. Adequate relief in a treat-
ment trial with IBS patients: a prospective assessment. Am J 
Gastroenterol 2009;104:912-919.  
7. Lembo A, Ameen VZ, Drossman DA. Irritable bowel syndrome: to-
ward an understanding of severity. Clin Gastroenterol Hepatol 
2005;3:717-725.
8. Koller M, Neugebauer EA, Augustin M, et al. Assessment of quality 
of life in health services research - conceptual, methodological and 
structural prerequisites. Gesundheitswesen 2009;71:864-872.  
9. Committee for Proprietary Medicinal Products (CPMP). 
Committee for Propriety Medicinal Products (CPMP): points to 
consider on adjustment for baseline convariates. Stat Med 
2004;23:701-709.
10. Bardhan KD, Bodemar G, Geldof H, et al. A double-blind, random-
ized, placebo-controlled dose-ranging study to evaluate the efficacy of 
alosetron in the treatment of irritable bowel syndrome. Aliment 
Pharmacol Ther 2000;14:23-34.
11. Payne A, Blanchard EB. A controlled comparison of cognitive ther-
apy and self-help support groups in the treatment of irritable bowel 
syndrome. J Consult Clin Psychol 1995;63:779-786.
Conflicts of interest: None.
DOI: 10.5056/jnm.2010.16.2.223